Study: Cholesterol medication can reduce the deaths of blood rotting patients

A wide study published in the journal “Frontiers in Immunology” revealed that medicine “statin”; It is mainly known for the treatment of cholesterol, can help reduce deaths among patients with intense infection, a serious life -threatening inflammatory condition. The researchers pointed out that the use of statin is associated with a low risk of death by 39% during the first 28 days of patients’ entry into the hospital, compared to patients who did not receive this medicine. The author, “Cayeeng Lee”, an associate professor at Tianjin Medical University Hospital in China, said the results indicate that statin medicine can provide extra protection for patients with intestan and improve their chances of survival. Intestine or blood rot is a serious life -threatening medical condition, it occurs when the immune system exaggerates its inflammatory response to an infection, leading to the failure of important organs. In the United States alone, about 750,000 patients are admitted to hospital annually due to sepsis, about 27% of them die, and in about 15% of cases, the sepsis develops into an infection shock, where a dangerous decrease in blood pressure and poor blood flow to the tissue, which increases the death rate to between 30% and 40%. The salvation of the patient’s life depends on rapid intervention, as traditional treatment includes antibiotics, intravenous fluids and reinforces blood pressure. The benefits of the new statatin are the study of the new study indicates that the addition of statins to the treatment protocol can significantly improve the chances of survival. The statistics are mainly known as their role in the prevention of cardiovascular disease as they reduce harmful cholesterol (LDL) and triglycerides, and good cholesterol (HDL) is lifted. But recent research shows greater benefits for these medicines, including the anti -inflammatory, immunosuppressive properties, anti -oxidants and clotting. The researchers relied on the Mimic-IV medical database, which contains unknown electronic health records of about 265,000 patients who were admitted to Beth Israel Desiconis Hospital in Boston between 2008 and 2019, and the study focused on adults with intended intestines. To avoid prejudice in the results, the researchers used a statistical technique called ‘match the degree of miles’, where patients who received statins were compared to others in medical properties, but they did not receive treatment. The final sample included 6070 patients who received the statins, and 6070 others did not receive. The results show a significant decrease in the death rate within 28 days in the group that received the statins by 14.3% compared to the other group. According to the study; Statins improve the results of blood -rot -patients through their multiple properties that go beyond mere cholesterol as it has anti -inflammatory effects that reduce the excessive cytokine storm that characterizes sepsis. It also works to improve the function of vascular lining and increase the production of nitric oxide, which improves blood flow, in addition to the anticoagulant characteristics that reduce the risk of precision clots, and its immune characteristics that help regulate the excessive immune response, which, according to recent studies, reduces death rate. However, several results were observed that patients who took statins spent longer on artificial breaths, an increase of 3 hours on average and in alternate kidney, an increase of 26 hours. The researchers attribute this to a ‘barter’ between reducing the risk of death and the extension of the duration of some supportive treatments. Additional analyzes also confirmed these results in patients with normal, excessive or obese people, but the same effect did not appear in weightlifting. Although the now random experiments, which are considered the golden standard in medical research, have not previously proved the benefit of the statins in the treatment of sepsis, researchers indicate that these experiments were limited by a few patients or did not take into account factors such as the type of statin, its dose and the timing of the beginning of the treatment. Kaeving Li added that the ideal experience should include a large number of patients, with accurate data on the type of statin, dose and duration of treatment, in addition to the potential effective factors. If these results are confirmed by larger clinical trials, the statins can become a significant part of the sepsis treatment protocol, which can save tens of thousands of lives annually. However, experts have warned against the rush to apply these results before more studies, especially with regard to optimal doses and the most effective types of statins.